newsfilter
← Latest News
Business Wire·

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation (NASDAQ:OMER) today announced an update on its progress toward planned resubmission of its biologics license application ("BLA") for narsoplimab, the company's first-in-class antibody targeting